Selected Publications

Yu, S., Mulero, M.C., Chen, W., Shang, X.,  Tian, S., Watanabe, J., Watanabe, A., Vorberg, T., Wong, C., Gately, D.,  and Howell, S.B.,  Therapeutic targeting of tumor cells rich in LGR stem cell receptors, Biocongugate Chem. 32: 376–384, 2021

 Sonowal, H., Zhang, H., Rice, W.R., Howell, S.B., Luxeptinib Disables NLRP3 Inflammasome-Mediated IL-1β release and Pathways Required for Secretion of Inflammatory Cytokines IL-6 and TNFα, Biochem Pharmacol, 195:114861, 20222.

Rice, W.R., Howell, S.B.,  Zhang, H., Rastgoo, N.,  Local, A., Kurtz, S.E., Lo, P.,  Bottomly, D., Wilmot, B, McWeeney, S.K., Druker, B/J., Tyner, J.W., Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia, Mol Cancer Ther, 21:1125-1135, 2022, doi: 10.1158/1535-7163.MCT-21-083

Wenzel AT, Champa D, Venkatesh H, Sun S, Tsai C-Y, Mesirov JP, Bui JD, Howell SB, Harismendy O. Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer, NPJ Syst Biol Appl 8:20;  doi: 10.1038/s41540-022-00230-z.

Wong, C.,  Mulero, M. C., Barth, E.I, Wang, K., Gately, D., Shang, X., Tikle. S., Rice, C., Howell, S.B., Exploiting the receptor-binding domains of RSPO1 to target LGR5-expressing stem cells in ovarian cancer, J. Pharm. Expt., in press, Feb 2023

Sonowal, H., Rice, W.G., Howell, S.B.,  Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma, PLOS One, in press, Feb 2023